UBS Group AG Sells 125 Shares of Amphastar Pharmaceuticals, Inc. (AMPH)
UBS Group AG reduced its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 1.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,349 shares of the company’s stock after selling 125 shares during the period. UBS Group AG’s holdings in Amphastar Pharmaceuticals were worth $136,000 as of its most recent filing with the SEC.
Several other large investors have also bought and sold shares of AMPH. Municipal Employees Retirement System of Michigan raised its stake in Amphastar Pharmaceuticals by 3.7% in the first quarter. Municipal Employees Retirement System of Michigan now owns 8,200 shares of the company’s stock valued at $119,000 after buying an additional 290 shares in the last quarter. Mason Street Advisors LLC raised its stake in Amphastar Pharmaceuticals by 7.0% in the first quarter. Mason Street Advisors LLC now owns 8,394 shares of the company’s stock valued at $122,000 after buying an additional 549 shares in the last quarter. Karp Capital Management Corp acquired a new stake in Amphastar Pharmaceuticals during the first quarter valued at approximately $193,000. Louisiana State Employees Retirement System raised its stake in Amphastar Pharmaceuticals by 1.4% in the first quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the company’s stock valued at $212,000 after buying an additional 200 shares in the last quarter. Finally, OppenheimerFunds Inc. acquired a new stake in Amphastar Pharmaceuticals during the first quarter valued at approximately $215,000. Institutional investors and hedge funds own 44.02% of the company’s stock.
Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ AMPH) traded down 1.31% on Friday, hitting $15.07. 35,772 shares of the stock were exchanged. The stock has a market cap of $691.86 million, a PE ratio of 195.71 and a beta of 1.65. Amphastar Pharmaceuticals, Inc. has a 52-week low of $12.05 and a 52-week high of $21.75. The company’s 50 day moving average is $17.33 and its 200-day moving average is $15.92.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its earnings results on Wednesday, August 9th. The company reported $0.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.05. The firm had revenue of $65.20 million for the quarter, compared to analysts’ expectations of $63.40 million. Amphastar Pharmaceuticals had a net margin of 1.61% and a return on equity of 2.43%. The firm’s revenue was down 4.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.23 earnings per share. Analysts predict that Amphastar Pharmaceuticals, Inc. will post $0.40 EPS for the current fiscal year.
Amphastar Pharmaceuticals announced that its board has authorized a share repurchase program on Wednesday, August 9th that authorizes the company to buyback $20.00 million in outstanding shares. This buyback authorization authorizes the company to buy up to 2.8% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s management believes its shares are undervalued.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/08/11/ubs-group-ag-sells-125-shares-of-amphastar-pharmaceuticals-inc-amph.html.
Several equities research analysts have recently commented on AMPH shares. TheStreet upgraded shares of Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a report on Monday, June 26th. Wells Fargo & Company restated a “buy” rating on shares of Amphastar Pharmaceuticals in a report on Saturday, July 22nd. Jefferies Group LLC reduced their price target on shares of Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday, May 10th. Piper Jaffray Companies set a $20.00 price target on shares of Amphastar Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, July 29th. Finally, BMO Capital Markets restated a “hold” rating and issued a $16.00 price target on shares of Amphastar Pharmaceuticals in a report on Monday, July 31st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $20.00.
In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, June 9th. The shares were sold at an average price of $17.07, for a total transaction of $170,700.00. Following the sale, the director now owns 28,844 shares of the company’s stock, valued at $492,367.08. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Michael A. Zasloff sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $17.01, for a total transaction of $255,150.00. Following the sale, the director now directly owns 47,411 shares in the company, valued at approximately $806,461.11. The disclosure for this sale can be found here. In the last ninety days, insiders sold 36,482 shares of company stock worth $620,125. 11.10% of the stock is owned by corporate insiders.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH).
Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.